baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

L&S Knock-Out AXSM/ DE000LX4LJW1 /

2024-10-07 8:08:18 AM	Chg.-	Bid10:00:20 PM	Ask10:00:20 PM	Underlying	Strike price	Expiration date	Option type
0.380EUR	-	- Bid Size: -	- Ask Size: -	Axsome Therapeutics ...	79.4161 -	2078-12-31	Call

GlobeNewswire 08-27 Axsome Therapeutics to Participate in Investor Conferences in September

GlobeNewswire 08-21 Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sando...

GlobeNewswire 08-05 Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 07-11 Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5

GlobeNewswire 06-05 Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories

GlobeNewswire 06-04 Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During...

GlobeNewswire 06-03 Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month

GlobeNewswire 05-30 Axsome Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire 05-29 Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function ...

GlobeNewswire 05-28 Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Ps...

GlobeNewswire 05-08 Axsome Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire 05-06 Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 05-01 Axsome Therapeutics Recognizes May as Mental Health Awareness Month

GlobeNewswire 04-15 Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurolog...

GlobeNewswire 04-10 Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6

GlobeNewswire 04-01 Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating...

GlobeNewswire 03-25 Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Nee...

GlobeNewswire 03-25 Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narc...

GlobeNewswire 03-19 Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depr...

GlobeNewswire 03-05 Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference

GlobeNewswire 02-20 Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Busines...

GlobeNewswire 01-23 Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20

GlobeNewswire 01-04 Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anti...

GlobeNewswire 2023-12-11 Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depr...

GlobeNewswire 2023-12-07 Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today

L&S Knock-Out AXSM/ DE000LX4LJW1 /

If you wish to receive reply to your feedback, please provide your email address.